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Abstract
Objectives The application of an enamel matrix derivative
(EMD) for regenerative periodontal surgery has been shown
to promote formation of new cementum, periodontal liga-
ment, and alveolar bone. In intrabony defects with a com-
plicated anatomy, the combination of EMD with various
bone grafting materials has resulted in additional clinical
improvements, but the initial cellular response of osteoblasts
coming in contact with these particles have not yet been
fully elucidated. The objective of the present study was to
evaluate the in vitro effects of EMD combined with a natural
bone mineral (NBM) on a wide variety of genes, cytokines,
and transcription factors and extracellular matrix proteins on
primary human osteoblasts.
Material and methods Primary human osteoblasts were seed-
ed on NBM particles pre-coated with versus without EMD
and analyzed for gene differences using a human osteogenesis
gene super-array (Applied Biosystems). Osteoblast-related
genes include those transcribed during bone mineralization,
ossification, bone metabolism, cell growth and differentia-
tion, as well as gene products representing extracellular
matrix molecules, transcription factors, and cell adhesion
molecules.
Results EMD promoted gene expression of various osteo-
blast differentiation markers including a number of collagen
types and isoforms, SMAD intracellular proteins, osteopon-
tin, cadherin, alkaline phosphatase, and bone sialoprotein.
EMD also upregulated a variety of growth factors including
bone morphogenetic proteins, vascular endothelial growth
factors, insulin-like growth factor, transforming growth fac-
tor, and their associated receptor proteins.
Conclusion The results from the present study demonstrate
that EMD is capable of activating a wide variety of genes,
growth factors, and cytokines when pre-coated onto NBM
particles.
Clinical relevance The described in vitro effects of EMD on
human primary osteoblasts provide further biologic support
for the clinical application of a combination of EMD with
NBM particles in periodontal and oral regenerative surgery.
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Introduction
Enamel matrix derivative (EMD) has been shown to pro-
mote periodontal regeneration by inducing formation of
cementum, periodontal ligament (PDL), and alveolar bone
which is clinically evidenced by probing depth reduction,
attachment gain, and radiographic defect fill [1–3]. The
major components of EMD are amelogenins, a family of
hydrophobic proteins derived from different splice variants
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and controlled by post-secretory processing from a single
gene that account for more than 95 % of the total protein
content [4]. These proteins self-assemble into supramolecu-
lar aggregates that form an insoluble extracellular matrix
that function to control the ultrastructural organization of the
developing enamel crystallites [4]. Other proteins found in
the enamel matrix include enamelin, ameloblastin (also
called amelin or sheathlin), amelotin, apin, and various
proteinases [5, 6]. The rationale for the clinical use of
EMD is the observation that enamel matrix proteins are
deposited onto the surface of developing tooth roots prior
to cementum formation [7].
Although histological studies in animals and humans
have provided evidence for periodontal regeneration and
substantial clinical improvements following the use of
EMD, concerns have been expressed regarding the vis-
cous nature of EMD, which may not be sufficient to
prevent flap collapse in periodontal defects with a com-
plicated anatomy [8, 9]. In order to overcome this po-
tential limitation and improve the clinical outcomes,
various combinations of EMD and different types of
grafting materials have been used [1–3, 10–16]. The
combination of EMD with a natural bone mineral of
bovine origin (NBM) has provided additional periodontal
regeneration and substantial clinical improvements when
compared to either NBM alone or EMD alone [1, 3,
10–14]. Recently, we have demonstrated that the combi-
nation of EMD with NBM particles enhances osteoblast
and PDL cell proliferation and differentiation in vitro
[17]. The aim of the present study was to investigate
more deeply the initial behavior of primary human osteo-
blasts exposed to this combination by assessing a wide
variety of osteoblast cytokines, growth factors, differenti-
ation markers, and extracellular matrix molecules using a
commercially available super-array.
Materials and methods
Surface coating with EMD
EMD was prepared according to Institut Straumann AG
standard operating protocols as previously discussed [18].
Thirty milligrams of EMD was dissolved in 3 ml of sterile
0.1 % acetic acid at 4 °C. For experiments, stock EMD
was diluted 100× in 0.1 M carbonate buffer at 4 °C to a
working concentration of 100 μg/ml in order to maintain
physiological pH. One milliliter of EMD solution was
poured onto 100 mg of NBM particles (BioOss, Geistlich
Pharma AG, Wolhusen, Switzerland) in 24-well culture
dishes and incubated overnight at 4 °C. Following incu-
bation, dishes were rinsed twice with 1 ml phosphate
buffered saline twice.
Human primary osteoblast isolation and differentiation
Human bone chips from a single donor were cultured
according to an explant model [19] under a protocol ap-
proved by the Ethics Committee, Katon Bern, Switzerland
as previously described [20]. Primary human osteoblasts
were detached from the tissue culture plastic using trypsin
solution (Invitrogen, Basel, Switzerland). Cells used for
experimental seeding were from passages 4–6. Osteoblasts
were seeded at a density of 50,000 cells in 24-well culture
plates (Falcon) for experimental seeding.
Super-array of osteogenic potential
The initial expression of osteoblast-related genes was exam-
ined after culture of cells for 24 h. Total RNA was isolated
using TRIZOL reagent and RNAeasy Mini kit (QIAGEN,
Basel, Switzerland). A TaqMan® Human Osteogenesis 96-
well Plate Super-array (4414096, Applied Biosystems,
Rotkreuz, Switzerland) was employed for the analysis.
Osteoblast-related genes include those transcribed during
bone mineralization, ossification, bone metabolism, cell
growth, and differentiation. The gene products represent
extracellular matrix molecules, transcription factors, and cell
adhesion molecules among others. Real-time RT-PCR was
performed according to manufacturer’s protocol using 20 μl
final reaction volume of TaqMan®’s One step Master Mix
kit (Applied Biosystems) as previously described [21]. RNA
quantification was performed using a Nanodrop 2000c
(Thermo Scientific, Waltham, MA, USA) and 100 ng of
total RNA was used per sample well. Gene fold increase
represent data from NBM particles pre-coated with EMD
versus NBM particles that were left uncoated.
Statistical analysis
Gene array analysis was performed for both control (n04)
and experimental groups (n04). Means and standard devia-
tions (SE) were calculated, and the statistical significance of
differences among each group were examined by student
t test between both groups (*, p values<0.05).
Results
Osteoblast regulation of transcription factors
and differentiation parameters
Analysis of gene array data revealed an increase of osteo-
blast differentiation genes across a wide variety of osteo-
blast differentiation markers and secreted proteins (Table 1).
Specifically, many collagen types and isoforms were
upregulated including collagen type I alpha 2 (3.4772 fold,
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p<0.0079), collagen type V alpha 1 (3.1376, p<0.1425),
collagen type 1, alpha 1 (2.5394, p<0.0369), collagen type
X11 alpha 1 (2.5253, p<0.0180), and collagen type XIV,
alpha 1 (1.7729, p<0.0417). Intracellular proteins responsible
for transducing extracellular signals (SMAD family)
were also upregulated by EMD when compared to control
uncoated samples (upregulation varied between 1.9375 and
3.6036 fold). EMD also upregulated a number of osteoblast
differentiation markers including osteonectin (5.1523 fold,
p<0.0026), osteopontin (4.1211, p<0.0441), cadherin 11
(3.0693, p<0.0456), bone sialoprotein (2.5758, p<0.0274),
and alkaline phosphatase (2.4090, p<0.0027).
Osteoblast regulation of osteoblast growth factors
An array of growth factors essential for osteoblast differenti-
ation were also quantified using real-time RT-PCR (Table 2).
In general, EMD had a positive impact on the release of
bonemorphogenetic proteins (BMPs) including BMP1 (6.6867
fold increase, p<0.0033), BMP2 (4.2685, p<0.0028), BMP6
(3.7190, p<0.0028), and BMP4 (3.0751<0.0226). EMD
also upregulated vascular endothelial growth factor A
and B (VEGF-A, VEGF-B, 4.8375, p<0.0231 and 2.3501,
p<0.0104, respectively), fibroblast growth factor 1 (FGF1,
3.4801, p<0.0132), insulin-like growth factor 2 (IGF2,
Table 1 Gene fold increase in osteoblast differentiation markers, transcription factors, and extracellular matrix proteins
GenBank Name Fold change SE p value
SPARC-Hs00277762_m1 Secreted protein, acidic, cysteine-rich (osteonectin) 5.1523 0.4429 0.0026
SPP1-Hs00959010_m1 Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I,
early T-lymphocyte activation 1)
4.1211 0.9317 0.0441
SMAD2-Hs00183425_m1 SMAD family member 2 3.6036 0.3579 0.0054
COL1A2-Hs00164099_m1 Collagen, type I, alpha 2 3.4772 0.3908 0.0079
SMAD3-Hs00232222_m1 SMAD family member 3 3.4075 0.3000 0.0040
COL5A1-Hs00609088_m1 Collagen, type V, alpha 1 3.1376 1.0815 0.1425
COL3A1-Hs00164103_m1 Collagen, type III, alpha 1 (Ehlers–Danlos syndrome type IV,
autosomal dominant)
3.0964 0.5120 0.0263
CDH11-Hs00156438_m1 Cadherin 11, type 2, OB-cadherin (osteoblast) 3.0693 0.6402 0.0456
IBSP-Hs00173720_m1 Integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) 2.5758 0.3907 0.0274
COL1A1-Hs00164004_m1 Collagen, type I, alpha 1 2.5394 0.4282 0.0369
COL12A1-Hs00189184_m1 Collagen, type XII, alpha 1 2.5253 0.3229 0.0180
ALPL-Hs00758162_m1 Alkaline phosphatase, liver/bone/kidney 2.4090 0.1523 0.0027
SMAD5-Hs00195437_m1 SMAD family member 5 2.0202 0.2773 0.0348
SMAD4-Hs00232068_m1 SMAD family member 4 1.9375 0.3029 0.0525
MINPP1-Hs00245149_m1 Multiple inositol polyphosphate histidine phosphatase, 1 1.7856 0.0613 0.0010
COL14A1-Hs00385388_m1 Collagen, type XIV, alpha 1 1.7729 0.2257 0.0417
TWIST1-Hs00361186_m1 Twist homolog 1 (acrocephalosyndactyly 3; Saethre–Chotzen
syndrome) (Drosophila)
1.3874 0.3476 0.3463
ARSE-Hs00163677_m1 Arylsulfatase E (chondrodysplasia punctata 1) 1.0910 0.0624 0.2415
COL18A1-Hs00181017_m1 Collagen, type XVIII, alpha 1 0.6487 0.1004 0.0396
Table 2 Gene fold increase in
osteoblast growth factors and
cytokines
GenBank Name Fold change SE p value
BMP1-Hs00241807_m1 Bone morphogenetic protein 1 6.6867 0.6575 0.0033
VEGFA-Hs00900054_m1 Vascular endothelial growth factor A 4.8375 0.8922 0.0231
BMP2-Hs00154192_m1 Bone morphogenetic protein 2 4.2685 0.3577 0.0028
BMP6-Hs00233470_m1 Bone morphogenetic protein 6 3.7190 0.2980 0.0028
FGF1-Hs00265254_m1 Fibroblast growth factor 1 (acidic) 3.4801 0.4692 0.0132
BMP4-Hs00370078_m1 Bone morphogenetic protein 4 3.0751 0.4782 0.0226
VEGFB-Hs00173634_m1 Vascular endothelial growth factor B 2.3501 0.2348 0.0104
IGF2-Hs00171254_m1 Insulin-like growth factor 2
(somatomedin A)
2.1332 0.2599 0.0223
TGFB1-Hs99999918_m1 Transforming growth factor, beta 1 1.8082 0.0965 0.0036
TGFB3-Hs00234245_m1 Transforming growth factor, beta 3 1.5939 0.1298 0.0196
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2.1332, p<0.0223) as well as transforming growth factor, beta
1 and 3 (TGFβ1, TGFβ3, 1.8082, p<0.0036 and
1.5939, p<0.0196 fold, respectively). Interestingly, EMD
showed an even more pronounced effect on the receptors
associated with each growth factor (Table 3). EMD increased
epidermal growth factor receptor 17.0332 fold, TGFβ recep-
tor 14.9025 fold, IGF1 receptor 6.2826 fold, BMP receptor
5.7594 fold, and FGF receptor 1 2.6171 fold (Table 3).
Discussion
The results from the present study demonstrate that EMD
has the ability to enhance cytokine and growth factor gene
expression as well as increase osteoblast differentiation
markers and transcription factors when combined onto
NBM particles. Previous in vitro research has documented
the role of EMD in both osteoblasts and PDL cells in
various cell culture systems [22]. EMD has a significant
influence on cell adhesion, cell proliferation, and cell differ-
entiation of many cell types by mediating cell attachment,
spreading, proliferation, and survival as well as expression
of transcription factors, growth factors, cytokines, extracel-
lular matrix constituents, and other molecules involved in
the regulation of bone remodeling [22].
The rational for choosing osteoblasts as a primary cell
source as opposed to PDL cells was to simulate in vivo
situations. Although EMD stimulates periodontal regenera-
tion, the cells that come in contact with bone grafting
particles pre-coated with EMD are typically osteoblasts as
PDL cells themselves generally attach and proliferate along
the root cementum. Despite primary human osteoblasts be-
ing harvested from a single donor, these conditions repre-
sent a more realistic clinical similarity when compared to
other single donor cell lines derived from various species
[23, 24]. Previously, many investigators have demonstrated
that EMD influence osteoblast differentiation when seeded
on standard tissue culture plastic using a wide variety of cell
lines from various species (MG63, SaOS, MC3T3, HSC-2,
mice/rat calvarial osteoblasts) [22].
In the present study, we observed that EMD enhanced
many growth factors and cytokines including cadherin gene
expression (Table 1). Interestingly, we have previously
shown that EMD upregulates the expression of vital osteo-
blast cell–cell communication and adhesion molecules N-
cadherin and connexin43 (intercellular gap junction channel
proteins) at early time points, which enhances the differen-
tiation and mineralization activity of osteoblasts [20]. EMD
also had a pronounced effect on SMAD intercellular pro-
teins (Table 1). The family of SMAD signal proteins is
utilized by many cell types including osteoblasts to trans-
duce extracellular signals from TGFβ from the cell mem-
brane to the nucleus [25]. Previously, it was observed that
EMD induced rapid translocation of SMAD2 into the nu-
cleus causing an increase in cell proliferation [26, 27].
Interestingly, results from our super-array revealed upregu-
lation of multiple SMAD proteins, with over threefold
increases in SMAD2 and SMAD3 (Table 1) demonstrating
a very plausible role of TGFβ for EMD-treated osteoblasts.
Furthermore, TGFβ1 and TGFB receptor were increased
1.8082 and 14.9025 fold, respectively, on EMD-coated
NBM particles. These results are consistent with other
authors who have demonstrated that EMD increased the
secretion of TGFβ1 and PDGF through intracellular cAMP
[28, 29].
EMD also stimulated a variety of growth factors contrib-
uting to osteoblast maturation (Table 2). These findings are
consistent with other authors who have analyzed the effects
of EMD on cells grown on cell culture plastic [30–32].
Recently, it was demonstrated that the effect of EMD on
cell proliferation was mediated through binding to amelo-
genins while the differentiation of progenitor cells was
caused mainly by the release of BMPs [30]. Furthermore,
it was shown that the receptors for BMPs played an impor-
tant role in differentiation of PDL cells in response to
mechanical stimulation and interleukin 1β [31]. In a
previous in vitro gene expression assay on periodontal
ligament cells treated with EMD on cell culture plastic,
EMD upregulated growth factors PDGF, BMPs, TGFβ,
and VEGF [32]. In this study, EMD was not only capable of
Table 3 Gene fold increase in osteoblast receptors associated with growth factors and cytokines
GenBank Name Fold change SE p value
EGFR-Hs00193306_m1 Epidermal growth factor receptor (erythroblastic leukemia viral
(v-erb-b) oncogene homolog, avian)
17.0332 4.8205 0.0449
TGFBR1-Hs00610319_m1 Transforming growth factor, beta receptor I (activin A receptor
type II-like kinase, 53 kDa)
14.9025 3.7939 0.0351
IGF1R-Hs00609566_m1 Insulin-like growth factor 1 receptor 6.2826 1.6289 0.0477
BMPR1A-Hs00831730_s1 Bone morphogenetic protein receptor, type IA 5.7594 1.0529 0.0202
FGFR1-Hs00241111_m1 Fibroblast growth factor receptor 1 (fms-related tyrosine kinase
2, Pfeiffer syndrome)
2.6171 0.9069 0.1748
TGFBR2-Hs00559661_m1 Transforming growth factor, beta receptor II (70/80 kDa) 2.3731 0.5244 0.0791
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increasing expression of osteoblast growth factors but also
their respective membrane surface receptors (Table 3). The
role of each of these receptors on EMD-induced proliferation
and differentiation requires further investigation.
Taken together, the present study has demonstrated that
the addition of EMD to NBM particles improves the initial
cell response of primary human osteoblast in vitro. The
results provide further evidence that EMD has an influence
on secreted extracellular matrix proteins, osteoblast tran-
scription factors, and differentiation markers as well as
growth factors and their associated receptors thus supporting
the clinical use of a combination of EMD with bone grafting
particles.
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